This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a McGill University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $672,436
Co-designing a Transnational AI-Powered Chatbot to Improve Access to Pre-Exposure Prophylaxis (PrEP) Among Migrants, Women, and Gay, Bisexual and Other Men Have Sex with Men in Canada, Ghana, and Germany: The MARVIN-CONNECT Study
CIHR · 2026 · Principal investigator
- $1,023,674
A randomized trial to compare effectiveness of 4 months Rifampin (4 RIF) with 9 months Isoniazid (9 INH) in the prevention of active TB in children: The P4v9 Trial
CIHR · 2010 · Co-investigator
Co-designing a Transnational AI-Powered Chatbot to Improve Access to Pre-Exposure Prophylaxis (PrEP) Among Migrants, Women, and Gay, Bisexual and Other Men Have Sex with Men in Canada, Ghana, and Germany: The MARVIN-CONNECT Study
Principal investigators: Lebouché, Bertrand; Achiche, Sofiane; Cox, John J; Engler, Kim; Enimil, Anthony; Hedrich, Tanguy; Hull, Mark W; Vicente, Sergio
Keywords: Access To Care; Artificial Intelligence (Ai); Chatbots; Co-Design; Hiv Prevention; Migrants; Multidisciplinary; Pre-Exposure Prophylaxis (Prep); Real-World Feasibilty Study; Underserved Populations (Women & Gbmsm)
A randomized trial to compare effectiveness of 4 months Rifampin (4 RIF) with 9 months Isoniazid (9 INH) in the prevention of active TB in children: The P4v9 Trial
Principal investigators: Menzies, Richard
Keywords: Child Health; Global Health; Latent Tb Infection; Randomized Trail; Tuberculosis Prevention; Tuberculosis Treatment
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.